GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Xcorporeal Inc (GREY:XCRP) » Definitions » ROC %

Xcorporeal (Xcorporeal) ROC % : -858.46% (As of Sep. 2009)


View and export this data going back to . Start your Free Trial

What is Xcorporeal ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Xcorporeal's annualized return on capital (ROC %) for the quarter that ended in Sep. 2009 was -858.46%.

As of today (2024-05-19), Xcorporeal's WACC % is 0.00%. Xcorporeal's ROC % is 0.00% (calculated using TTM income statement data). Xcorporeal earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Xcorporeal ROC % Historical Data

The historical data trend for Xcorporeal's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xcorporeal ROC % Chart

Xcorporeal Annual Data
Trend Feb99 Feb00 Dec01 Dec02 Dec03 Dec04 Dec05 Dec06 Dec07 Dec08
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -11.90 -18.39 -798.21 -6,955.74 -7,159.64

Xcorporeal Quarterly Data
Dec04 Mar05 Jun05 Sep05 Dec05 Mar06 Jun06 Sep06 Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -13,178.70 -2,718.18 -2,221.00 -1,310.77 -858.46

Xcorporeal ROC % Calculation

Xcorporeal's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2008 is calculated as:

ROC % (A: Dec. 2008 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2007 ) + Invested Capital (A: Dec. 2008 ))/ count )
=-31.893 * ( 1 - -0.01% )/( (0.396 + 0.495)/ 2 )
=-31.8961893/0.4455
=-7,159.64 %

where

Xcorporeal's annualized Return on Capital (ROC %) for the quarter that ended in Sep. 2009 is calculated as:

ROC % (Q: Sep. 2009 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2009 ) + Invested Capital (Q: Sep. 2009 ))/ count )
=-6.168 * ( 1 - 0% )/( (0.537 + 0.9)/ 2 )
=-6.168/0.7185
=-858.46 %

where

Note: The Operating Income data used here is four times the quarterly (Sep. 2009) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Xcorporeal  (GREY:XCRP) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Xcorporeal's WACC % is 0.00%. Xcorporeal's ROC % is 0.00% (calculated using TTM income statement data). Xcorporeal earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Xcorporeal ROC % Related Terms

Thank you for viewing the detailed overview of Xcorporeal's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Xcorporeal (Xcorporeal) Business Description

Traded in Other Exchanges
N/A
Address
80 Empire Drive, Lake Forest, CA, USA, 92630
Website
Xcorporeal Inc is a medical device company, developing an innovative extra-corporeal platform technology to be used in devices to replace the function of various human organs.
Executives
Kelly J. Mccrann director, officer: Chairman and CEO 11150 SANTA MONICA BLVD #1500, LOS ANGELES CA 90025
Daniel S Goldberger officer: Chief Executive Officer 24 CARPENTER ROAD, CHESTER NY 10918
Marc G Cummins director C/O PRIME LOGIC CAPITAL, LLC, 135 EAST 57TH STREET, 11TH FLOOR, NEW YORK NY 10022
Prime Logic Capital, Llc 10 percent owner 135 EAST 57TH STREET, 11TH FLOOR, NEW YORK NY 10022
Robert Weinstein officer: Chief Financial Officer 3960 HOWARD HUGHES PARKWAY, SUITE 500, LAS VEGAS NV 89169
Terren S Peizer director, 10 percent owner, officer: Executive Chairman 11111 SANTA MONICABLVD STE.500, LOS ANGELES CA 90025
Jay Wolf director 981 LINDA FLORA DRIVE, LOS ANGELES, CA 90049
Herve De Kergrohen director 22 CHEMIN DU NANTET, COLLONGE-BELLERIVE V8 CH1245
Nicholas Sheridan Lewin director 3 WEST 57TH ST., 8TH FLOOR, NEW YORK NY 10019
Lawrence Lacerte 10 percent owner C/O TERAGLOBAL COMMUNICATIONS CORP, 9171 TOWNE CENTRE DRIVE SUITE 600, SAN DIEGO CA 92122

Xcorporeal (Xcorporeal) Headlines